GamaMabs and MedImmune Enter Licensing Agreement to Develop ADC Targeting Cancer

GamaMabs and MedImmune Enter Licensing Agreement to Develop ADC Targeting Cancer

Paris and Toulouse, France, October 10, 2017 – GamaMabs Pharma, a biotechnology company developing optimized therapeutic antibodies targeting AMHR2 for…